At PCR, Valves Steal The Show, But DES Shine

Every year for just about the past decade, drug-eluting stents dominated the agenda at the Paris Course on Revascularization and just about any meeting where interventional cardiologists gathered to hear the latest in technology and practice innovation. But without question, the star of this year’s PCR was percutaneous heart valves and, in particular the revolution in transaortic valve replacement that has been ushered in by Edwards Lifesciences., which acquired Percutaneous Valve Technologies several years ago, and Medtronic., as a result of its more recent CoreValve acquisition.

Every year for just about the past decade, drug-eluting stents (DES) dominated the agenda at the Paris Course on Revascularization (PCR) – and just about any meeting where interventional cardiologists gathered to hear the latest in technology and practice innovation. But without question, the star of this year's PCR, Europe's leading gathering of interventionalists, was percutaneous heart valves and, in particular the revolution in transaortic valve replacement that has been ushered in by Edwards Lifesciences Corp., which acquired Percutaneous Valve Technologies (PVT) several years ago, and Medtronic PLC, as a result of its more recent CoreValve (now called Medtronic CoreValve LLC) acquisition. [See Deal][See Deal]

Indeed, the self-styled Great Debate that kicked off this year's PCR was all about TAVI (transaortic valve implantation), but it...

More from Archive

More from In Vivo

Podcast: Scancell’s Cancer Vaccine Progress With NHS Partnership

 
• By 

In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.

Geopolitical Volatility Not Dimming A Healthy Mid-Term Outlook For Life Sciences Deals

 
• By 

New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.

Navigating the GLP-1 Opportunity In China: Strategic Imperatives For Western Pharma

 
• By 

The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.